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Purpose
Subject blinding is critical to minimizing bias in rando-
mized controlled trials (RCTs). Irritable Bowel Syndrome
(IBS) is a complex and often chronic condition with physi-
cal and psychological components. For many patients, psy-
chological issues such as anxiety and stress can exacerbate
the existing condition. Given the mind-body relationship
in this illness, we explored if an individual’s belief in treat-
ment and a belief in being randomized to an active treat-
ment group could impact their self-reported health
outcomes.
Methods
In the parent study, data were gathered in a three-week
randomized controlled trial (n=262) testing the therapeutic
effect of an Augmented (supportive) patient-practitioner
relationship versus a Limited patient-practitioner relation-
ship versus wait list in reducing the symptoms of IBS.
During the first three weeks of the trial, all treatments were
given in the context of biweekly sham acupuncture treat-
ments to allow the effects of patient-practitioner relation-
ship to be isolated. The second three weeks of the trial
began with a blind rerandomization of subjects in the two
treatment arms to either continue sham acupuncture or
begin real (insertive) acupuncture. Symptom data, expecta-
tions, and beliefs concerning blinding were collected at
baseline, 3, and 6 weeks. Expectations of treatment group
assignment (insertive or sham) and symptom improvement
were collected after the first treatment and before weeks 3
and 6 data collection.
Results
For all six of our expectancy and belief variables, the
Augmented and insertive treatment groups had more
positive reports compared to the Limited and sham acu-
puncture group, respectively; this trend continued in
reported symptom relief as well.
Conclusion
The risk of subject unblinding may be related to quali-
ties of the patient-practitioner relationship and treat-
ment experience; a better understanding of blinding as a
data safeguard is necessary.
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